The Phosphoinositide 3-Kinase (PI3K)/AKT Signaling Pathway as a Therapeutic Target for the Treatment of Human Acute Myeloid Leukemia (AML)

MLA

Roberta Bortul, et al. “The Phosphoinositide 3-Kinase (PI3K)/AKT Signaling Pathway as a Therapeutic Target for the Treatment of Human Acute Myeloid Leukemia (AML).” Current Signal Transduction Therapy, vol. 2, Sept. 2007, pp. 246–56. EBSCOhost, https://doi.org/10.2174/157436207781745373.

APA

Roberta Bortul, Maria Nyakern, Camilla Evangelisti, Pier Luigi Tazzari, Lucio Cocco, Alberto M. Martelli, & Giovanna Tabellini. (2007). The Phosphoinositide 3-Kinase (PI3K)/AKT Signaling Pathway as a Therapeutic Target for the Treatment of Human Acute Myeloid Leukemia (AML). Current Signal Transduction Therapy, 2, 246–256. https://doi.org/10.2174/157436207781745373

Chicago

Roberta Bortul, Maria Nyakern, Camilla Evangelisti, Pier Luigi Tazzari, Lucio Cocco, Alberto M. Martelli, and Giovanna Tabellini. 2007. “The Phosphoinositide 3-Kinase (PI3K)/AKT Signaling Pathway as a Therapeutic Target for the Treatment of Human Acute Myeloid Leukemia (AML).” Current Signal Transduction Therapy 2 (September): 246–56. doi:10.2174/157436207781745373.